The modulation of RNA splicing by small molecules has emerged as a promising strategy for treating pathogenic infections, human genetic diseases, and cancer; however, the principles by which splicing ...

Rgenta to receive a cash upfront and pre-option milestone payments Rgenta has the potential to receive milestone payments, royalties, and a future equity investment WOBURN, Mass., Dec. 4, 2024 ...

In the first step of spliceosome assembly, an snRNA molecule known as U1 snRNA binds to the 5' splice site at the beginning of the intron. Until now, it had been thought that the binding strength ...

Skyhawk Therapeutics Inc. signed on to work with Ipsen SA in a neurological disease-focused deal worth potentially $1.8 billion to discover and develop novel small molecules that modulate RNA. The ...

The spliceosome, which forms on introns, is composed of proteins and noncoding RNAs called small nuclear RNAs (snRNAs). In the first step of spliceosome assembly, an snRNA molecule known as U1 snRNA ...

WALTHAM, Mass.--(BUSINESS WIRE)--Arrakis Therapeutics, a biopharmaceutical company pioneering the discovery of a new class of small molecule medicines that directly target RNA, today announced that ...

Pharma giant GSK is buying into Rgenta Therapeutics’ mission to develop a pipeline of oral RNA-targeting small molecules. The new partners aim to develop new splice modulators for multiple disease ...

Adding another name to an impressive roster of partners assembled over the past few years, Skyhawk Therapeutics Inc. inked a deal with Merck KGaA aimed at discovering small-molecule RNA-targeted drugs ...

Fluorogenic DNA aptamers produce light only in the correct structural state, enabling programmable molecular logic, biosensing, DNA origami integrity reporting, and reusable mRNA detection through ...

Biologists have discovered a new type of RNA-splicing regulation that helps to determine which protein-coding exons will be included in messenger RNA transcripts. RNA splicing is a cellular process ...